Illumina, Inc. Hits New 52-Week High of USD 182.69

Illumina, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 182.69 on June 25, 2026. This achievement underscores the company's robust performance, particularly as it has recorded a remarkable 66.45% increase over the past year, significantly outpacing the S&P 500's performance of 20.77%. With a market capitalization of USD 22,581 million, Illumina operates within the mid-cap segment, showcasing its substantial presence in the industry. The company maintains a price-to-earnings (P/E) ratio of 35.00, reflecting its valuation relative to earnings. Additionally, Illumina's return on equity stands at an impressive 23.44%, indicating effective management and profitability. Despite a dividend yield of 0.00%, the company's financial health is further illustrated by a low debt-to-equity ratio of 0.16 and a price-to-book ratio of 8.29. The stock's previous 52-week low was recorded at USD 88, highlighting the significant upward trajectory it has experienced in recent months.